Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Van Drew, Jefferson [R-NJ-2]

Rep. Van Drew, Jefferson [R-NJ-2]

United States · Official source

Records

2,303 records where Rep. Van Drew, Jefferson [R-NJ-2] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 9988 (119th)referred

FASTER Act of 2026

United States · United States Congress · 30 July 2026

Bill· HRH.R. 9829 (119th)referred

ORTHO Act

United States · United States Congress · 22 July 2026

Bill· HRH.R. 9723 (119th)reported

Fit Future Act

United States · United States Congress · 16 July 2026

Bill· HRH.R. 9655 (119th)referred

FAIR Data Act

United States · United States Congress · 13 July 2026

Bill· HRH.R. 9535 (119th)referred

Securing Agriculture's Workforce Act of 2026

United States · United States Congress · 30 June 2026

Securing Agriculture's Workforce Act of 2026 This bill expands the H-2A agricultural visa program; creates online platforms for H-2A employers, workers, and agencies; and codifies certain wage calculations. Under current law, workers on H-2A visas are only allowed to perform agricultural work of a seasonal or temporary nature. Under the bill, the seasonal work requirement is removed, thus allowing H-2A workers to qualify for agricultural work that occurs year-round. The bill also expands the type of agricultural work that qualifies, including reforestation, aquaculture, and livestock work. The Department of Agriculture must issue rules to define agricultural labor or services for purposes of the H-2A program. The bill also establishes an H-2A visa pathway for current unauthorized agricultural workers who otherwise meet requirements. The Department of Labor must maintain a national, publicly accessible online job registry and database of all job offers submitted by employers seeking a labor certification required to employ H-2A workers. The Department of Homeland Security must establish an online platform for employers to submit information and documentation for review by federal agencies in the course of admitting H-2A workers. The H-2A program requires employers to provide workers with wage rates at or above those set in regulations and such wages must not adversely affect the wages and working conditions of workers similarly employed in the United States. The bill codifies the current calculation method for the adverse effect wage rate as set in regulation. 

Bill· HRH.R. 9169 (119th)referred

PKD Cures Act

United States · United States Congress · 4 June 2026

Bill· HRH.R. 9078 (119th)referred

LEASH Act of 2026

United States · United States Congress · 29 May 2026

Bill· HRH.R. 8964 (119th)referred

DONOR Milk Act

United States · United States Congress · 21 May 2026

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.